SPCs are an intellectual property right that grants an extension of up to 5 years on a 20-year patent term for an innovative pharmaceutical. The goal of the SPC is to offset the loss of patent protection that occurs during the development and clinical trials of a generic or biosimilar.
The European Commission has launched a public consultation on supplementary protection certificates (SPCs) and patent research exemptions. Changes to the ways in which SPCs are administered in the European Union could have a significant impact on the biosimilars marketplace.
SPCs are an intellectual property right that grants an extension of up to 5 years on a 20-year patent term for an innovative pharmaceutical. The goal of the SPC is to offset the loss of patent protection that occurs during the development and clinical trials of a generic or biosimilar.
Bolar patent exemptions, which are intended to speed market entry of generic therapies, provide exemptions to patent protection, even in cases in which SPCs are in force. These exemptions state that some pre-market activities cannot be regarded as infringements of a patent or SPC.
However, Martin Dræbye Gantzhorn and Emil Bjerrum, both of Denmark law firm Bech-Bruun, explain that because SPCs are granted and enforced at a national level, rather than at an EU level, confusion about, and difficulties with, these certificates and their related bolar exemptions are widespread.
For example, in some EU member states, bolar exemptions do not permit access to active pharmaceutical ingredients for the purpose of biosimilar development. In other states, it is not clear in the local law whether exemptions may be used for activities related to marketing drugs. Gantzhorn and Bjerrum also point out that bolar exemptions have been subject to stakeholder questioning insofar as they may disadvantage EU manufacturers; if EU drug makers are not allowed to produce pharmaceuticals for the non-EU market during the SPC term, developers located outside the EU will have an advantage in gaining early market share in these nations.
SPCs have also been subject to question in the biosimilars context due to the nature of biosimilar therapies themselves; SPCs cover the active ingredient or combination of active ingredients in a product. Because biosimilars are, by definition, only highly similar to their references, there remains some question as to whether SPCs can be applied to forestall biosimilar development. This question has been highlighted in Norway, where the judicial system first determined that SPCs did not apply to follow-on biologics, then overturned the decision in an appellate court.
The new consultation is intended to gain feedback from stakeholders in order to determine whether the Commission should take further legislative action concerning the certificates and waivers. Responses will be collected via online questionnaire, and results will be published by the Commission.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.